Crescita Therapeutics Inc.
CTX.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.30% | 23.55% | 16.96% | -1.99% | 9.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.30% | 23.55% | 16.96% | -1.99% | 9.86% |
| Cost of Revenue | -6.74% | 41.75% | 31.46% | 20.26% | 45.08% |
| Gross Profit | 21.59% | 9.00% | 4.92% | -19.47% | -14.49% |
| SG&A Expenses | -1.76% | -5.73% | -1.36% | -0.28% | 5.26% |
| Depreciation & Amortization | -5.38% | -40.98% | -48.55% | -54.08% | -50.19% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.51% | 9.27% | 7.13% | 3.08% | 15.10% |
| Operating Income | 69.89% | 72.07% | 43.36% | -40.08% | -61.88% |
| Income Before Tax | 98.55% | 118.67% | 53.55% | -44.96% | -77.70% |
| Income Tax Expenses | 165.00% | -106.91% | -106.91% | -104.67% | -102.97% |
| Earnings from Continuing Operations | 98.22% | 117.82% | 57.05% | -26.55% | -36.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.22% | 117.82% | 57.05% | -26.55% | -36.50% |
| EBIT | 69.89% | 72.07% | 43.36% | -40.08% | -61.88% |
| EBITDA | 118.03% | 124.48% | 66.98% | -117.79% | -248.91% |
| EPS Basic | 98.08% | 118.67% | 55.73% | -32.41% | -43.25% |
| Normalized Basic EPS | 132.01% | 126.85% | 47.90% | -58.76% | -98.83% |
| EPS Diluted | 96.62% | 115.85% | 54.86% | -32.99% | -43.72% |
| Normalized Diluted EPS | 131.86% | 126.68% | 47.74% | -58.76% | -98.83% |
| Average Basic Shares Outstanding | -2.61% | -3.03% | -3.82% | -4.25% | -4.44% |
| Average Diluted Shares Outstanding | -2.46% | -2.88% | -3.69% | -4.25% | -4.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |